The role of GM-CSF in the immune response against aPAP-associated infections raises the question, however, of why more opportunistic infections are not seen in patients who receive anti–GM-CSF therapy in patients with rheumatoid arthritis and psoriasis. Here, CSF2 is linked to infection.